Severe acute respiratory syndrome

Roche receives CE mark for the use of saliva samples with cobas SARS-CoV-2 Qualitative test on cobas 6800/8800 Systems

Retrieved on: 
Friday, December 17, 2021

PLEASANTON, Calif., Dec. 17, 2021 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its cobas® SARS-CoV-2 Qualitative test has received CE mark for the use of saliva samples in the detection of SARS-CoV-2 on the widely available, high-throughput cobas® 6800/8800 Systems. This non-invasive test is for any individual, including those suspected of COVID-19 and those without symptoms. Saliva sample collection represents a convenient testing approach for patients, who can easily self-collect their own samples.

Key Points: 
  • PLEASANTON, Calif., Dec. 17, 2021 /PRNewswire/ --Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its cobas SARS-CoV-2 Qualitative test has received CE mark for the use of saliva samples in the detection of SARS-CoV-2 on the widely available, high-throughput cobas 6800/8800 Systems.
  • Saliva sample collection represents a convenient testing approach for patients, who can easily self-collect their own samples.
  • "Expanding sensitive testing to include a non-invasive, easy-to-collect sample type such as saliva helps to improve access to screening for more people.
  • The test also provides patients with the option to self-collect their saliva sample on site, following the instructions of a healthcare professional.

$11+ Billion Respiratory Protection Equipment Markets - Global Forecasts from 2021 to 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 17, 2021

The "Respiratory Protection Equipment Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Respiratory Protection Equipment Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The global respiratory protection equipment market is evaluated at US$ 6.879 billion for the year 2019 growing at a CAGR of 7.04% reaching the market size of US$ 11.076 billion by the year 2026.
  • Regulations by various governments involving workplace security are the major driving force for the global respiratory protection equipment market.
  • Several regulatory organizations have recommended various companies and governments to increase their manufacturing of respiratory protective equipment, including respirators and breathing apparatuses.

BlueDot, Inc. and Huron Join Forces to Strengthen an Organization’s Response to Epidemics

Retrieved on: 
Thursday, November 4, 2021

The COVID-19 pandemic has sent shockwaves through the world with its widespread morbidity and economic impact.

Key Points: 
  • The COVID-19 pandemic has sent shockwaves through the world with its widespread morbidity and economic impact.
  • As nations and multinationals look beyond the pandemic, they need solutions that can help them better protect people and mitigate the instability of future epidemics.
  • Founded in 2013, BlueDot is the first epidemic intelligence platform that provides global and industry leaders, and corporations with the insights to detect, assess, and respond to epidemics.
  • BlueDot empowers governments and organizations to act faster and with more confidence to manage epidemics and allows multinational businesses to respond with greater agility and resilience.

Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target Indications

Retrieved on: 
Wednesday, October 20, 2021

NASH is also a metabolic disease where, much like diabetes, lyn kinase expression could be an ideal pathway to developing next-generation treatments.

Key Points: 
  • NASH is also a metabolic disease where, much like diabetes, lyn kinase expression could be an ideal pathway to developing next-generation treatments.
  • Regarding pulmonary edema, MLR-1023 is clearly differentiated from commonly used therapeutics today, including anti-inflammatory drugs and vaccines.
  • Adhera also has exclusive rights to develop MLR-1023 for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation diseases and conditions.
  • Melior Discovery and Melior Pharmaceuticals are privately held and located in Exton, PA. For more information, visit www.meliordiscovery.com and www.Meliorpharmaceuticals.com .

Vicore obtains SARS coronavirus patent for C21 in the USA

Retrieved on: 
Wednesday, September 22, 2021

GOTHENBURG, Sweden, Sept. 22, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, today announces that the U.S. Patent and Trademark Office (USPTO) has granted patent number US11,123,329 covering the use of C21 to treat infections caused by Severe Acute Respiratory Syndrome (SARS) coronavirus (CoV), including SARS-CoV-2.

Key Points: 
  • GOTHENBURG, Sweden, Sept. 22, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, today announces that the U.S. Patent and Trademark Office (USPTO) has granted patent number US11,123,329 covering the use of C21 to treat infections caused by Severe Acute Respiratory Syndrome (SARS) coronavirus (CoV), including SARS-CoV-2.
  • "This C21/CoV patent gives Vicore patent protection in the US market until December 2040."
  • A major clinical impact of C21 on respiratory function in COVID-19 was documented in a recent phase 2 trial showing that C21 reduced the need for supplemental oxygen in hospitalized patients by 90%.
  • "The use of C21 to promote accelerated resolution of lung damage by SARS-CoV-2 and related conronaviruses is a promising and innovative therapeutic approach" said Johan Raud, CSO of Vicore.

Vicore obtains SARS coronavirus patent for C21 in the USA

Retrieved on: 
Wednesday, September 22, 2021

GOTHENBURG, Sweden, Sept. 22, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, today announces that the U.S. Patent and Trademark Office (USPTO) has granted patent number US11,123,329 covering the use of C21 to treat infections caused by Severe Acute Respiratory Syndrome (SARS) coronavirus (CoV), including SARS-CoV-2.

Key Points: 
  • GOTHENBURG, Sweden, Sept. 22, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, today announces that the U.S. Patent and Trademark Office (USPTO) has granted patent number US11,123,329 covering the use of C21 to treat infections caused by Severe Acute Respiratory Syndrome (SARS) coronavirus (CoV), including SARS-CoV-2.
  • "This C21/CoV patent gives Vicore patent protection in the US market until December 2040."
  • A major clinical impact of C21 on respiratory function in COVID-19 was documented in a recent phase 2 trial showing that C21 reduced the need for supplemental oxygen in hospitalized patients by 90%.
  • "The use of C21 to promote accelerated resolution of lung damage by SARS-CoV-2 and related conronaviruses is a promising and innovative therapeutic approach" said Johan Raud, CSO of Vicore.

Global Above the Neck Protective Equipment Market Outlook to 2026: Respiratory Protection Segment Remains Dominant Due to Ongoing COVID-19 Pandemic - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 25, 2021

The "Global Above the Neck Protective Equipment Market Outlook to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Above the Neck Protective Equipment Market Outlook to 2026" report has been added to ResearchAndMarkets.com's offering.
  • Persistent technological advancement and innovations in the Above the Neck Protective Equipment are expected to drive the market over the forecast period.
  • It is essential to wear the right protection equipment tools such as earplugs, earmuffs, hard hats, full-face masks, etc.
  • By product type, the respiratory protection segment is expected to be the dominant market shareholder due to the ongoing Covid-19 pandemic during the forecast period.

Global Personal Protective Equipment (PPE) Market Outlook to 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 9, 2021

The "Global Personal Protective Equipment (PPE) Market Outlook to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Personal Protective Equipment (PPE) Market Outlook to 2026" report has been added to ResearchAndMarkets.com's offering.
  • Global personal protective equipment market is expected to witness a considerable growth rate during the forecast period.
  • Outbreaks of epidemics and pandemics such as Ebola, severe acute respiratory syndrome (SARS), or coronavirus (COVID-19) lead to increasing demand for Personal Protective Equipment.
  • The global personal protective equipment market was found to be consolidated.

Worldwide Medical Refrigerators Industry to 2028 - by Product Type, Design Type, Door Type, Temperature Control Range, and End-user - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 5, 2021

The "Medical Refrigerators Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product Type, Design Type, Door Type, Temperature Control Range, and End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Refrigerators Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product Type, Design Type, Door Type, Temperature Control Range, and End User" report has been added to ResearchAndMarkets.com's offering.
  • The report highlights the key factors driving the market growth and prominent players with their developments in the market.
  • Based on design type, the medical refrigerators market is segmented into explosion-proof refrigerators, undercounter medical refrigerators, countertop medical refrigerators, and flammable material storage refrigerators.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the medical refrigerators market.

Yocova: Rehiring and retraining cockpit and cabin crews. This time it's personnel!

Retrieved on: 
Thursday, August 5, 2021

LONDON, Aug. 5, 2021 /PRNewswire/ -- "Unprecedented" has probably the most used word in articles on many business topics since the first quarter of 2020. Given the shock waves all around the world caused by the COVID-19 pandemic, it is hardly surprising.

Key Points: 
  • On the human side, the pandemic brought huge numbers of pilot and cabin crew furloughs and redundancies which were incredibly painful for many of those affected.
  • "For those crews flying on small regional jets and turboprops, the future looks brighter than for the pilots and cabin crew on medium and heavy jets.
  • The domestic aviation markets of the world are recovering much quicker than international markets because of the quarantine restrictions and international travel bans.
  • One of the key elements of bringing crew back online is the actual process of call backs and rehiring.